Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs W.R. Berkley Corporation Common Stock (WRB) Price & Performance

Moderna, Inc.Trade
W.R. Berkley Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs W.R. Berkley Corporation Common Stock — how do they compare? Moderna, Inc. trades at $222.44 (market cap $90.35B), while W.R. Berkley Corporation Common Stock trades at $74.93 (market cap $27.40B). The key difference: Moderna, Inc. is far larger — about 3.3× W.R. Berkley Corporation Common Stock's market cap, and W.R. Berkley Corporation Common Stock pays a 0.54% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and W.R. Berkley Corporation Common Stock for 0 Days on average.

MRNAWRB
Market Cap
$90.35B$27.40B
Volume
16,579,5842,015,378
Sector
HealthFinancials
52-Week High
$226.30$78.10
52-Week Low
$22.36$63.54
Typical Hold Time
59 Days0 Days
Enterprise Value
$86.50B$27.64B
Dividend Yield
—0.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.

The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.

W.R. Berkley Corporation Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRNA
83% Buy17% Sell
Avg holding period · 59 Days
WRB
100% Buy0% Sell
Avg holding period · 0 Days

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →

About W.R. Berkley Corporation Common Stock

W.R. Berkley Corporation is an insurance holding company that underwrites commercial property and casualty insurance and reinsurance through its Insurance and Reinsurance & Monoline Excess segments.

Read more on WRB →